AVZO-023

DRUG2 trials

Sponsors

Avenzo Therapeutics Inc., Avenzo Therapeutics, Inc.

Conditions

Advanced CancerHR+, HER2-, Advanced Breast CancerHR+/HER2- Breast Cancer

Phase 1

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

RecruitingNCT06998407

Avenzo Therapeutics, Inc.HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer

Start: 2025-08-20End: 2030-08-01Target: 380Updated: 2026-08-10

ORION-1: A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-023 as a single agent, and in combination with AVZO-021 and/or endocrine therapy in patients with advanced solid tumors

Not yet recruitingCTIS2026-525948-15-00

Avenzo Therapeutics Inc.Advanced Cancer

Target: 28Updated: 2026-10-29

Related Papers

PS5-12-17: A phase 1/2 study of AVZO-023, a next-generation selective cyclin-dependent kinase 4 inhibitor (CDK4i), as a single agent and in combination with AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), and/or endocrine therapy in patients with advanced solid tumors

Clinical Cancer Research2026-02-17